These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 1373767

  • 1. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
    de Klerk JM, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP.
    J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
    [Abstract] [Full Text] [Related]

  • 2. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
    de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Quirijnen JM, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
    [Abstract] [Full Text] [Related]

  • 3. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
    De Klerk JM, Zonnenberg BA, Blijham GH, Van Het Schip AD, Hoekstra A, Han SH, Quirijnen JM, Van Dijk A, Van Rijk PP.
    Anticancer Res; 1997 Feb; 17(3B):1773-7. PubMed ID: 9179233
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C.
    J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
    [Abstract] [Full Text] [Related]

  • 5. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
    de Klerk JM, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, Rutgers DH, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
    [Abstract] [Full Text] [Related]

  • 6. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F, Herberg A, Spadaro P, Restifo Pecorella G, Baldari S, Aricò D, Altavilla G, Baldari S.
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [Abstract] [Full Text] [Related]

  • 7. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K, Hliscs R, Kropp J, Runge R, Knapp FF, Franke WG.
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [Abstract] [Full Text] [Related]

  • 8. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
    de Klerk JM, Zonnenberg BA, Krouwer HG, Blijham GH, van Dijk A, van het Schip AD, van Die J, van Rijk PP.
    J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
    de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Stokkel MP, Han SH, Blijham GH, van Rijk PP.
    J Nucl Med; 1994 Sep; 35(9):1423-8. PubMed ID: 8071686
    [Abstract] [Full Text] [Related]

  • 10. [Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
    Klutmann S, Bohuslavizki KH.
    MMW Fortschr Med; 1999 Nov 04; 141(44):38-9. PubMed ID: 10912142
    [Abstract] [Full Text] [Related]

  • 11. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF, Guhlke S, Biersack HJ.
    J Clin Oncol; 2003 Aug 01; 21(15):2869-75. PubMed ID: 12885803
    [Abstract] [Full Text] [Related]

  • 12. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
    Maxon HR, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, Smith H, Moulton JS, Williams CC, Ehrhardt GJ.
    J Nucl Med; 1991 Oct 01; 32(10):1877-81. PubMed ID: 1717669
    [Abstract] [Full Text] [Related]

  • 13. 186Re-etidronate in breast cancer patients with metastatic bone pain.
    Han SH, Zonneberg BA, de Klerk JM, Quirijnen JM, van het Schip AD, van Dijk A, Blijham GH, van Rijk PP.
    J Nucl Med; 1999 Apr 01; 40(4):639-42. PubMed ID: 10210223
    [Abstract] [Full Text] [Related]

  • 14. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
    Palmedo H, Bender H, Schomburg A, Grünwald F, Schöneich G, Zamorra P, Reichmann K, Dierke-Dzierzon C, Mallmann P, Biersack HJ.
    Nuklearmedizin; 1996 Apr 01; 35(2):63-7. PubMed ID: 8721578
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain.
    Quirijnen JM, Han SH, Zonnenberg BA, de Klerk JM, van het Schip AD, van Dijk A, ten Kroode HF, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Sep 01; 37(9):1511-5. PubMed ID: 8790203
    [Abstract] [Full Text] [Related]

  • 16. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
    Han SH, De Klerk JM, Zonnenberg BA, Tan S, Van Rijk PP.
    Q J Nucl Med; 2001 Mar 01; 45(1):84-90. PubMed ID: 11456380
    [Abstract] [Full Text] [Related]

  • 17. Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model.
    Geldof AA, van den Tillaar PL, Newling DW, Teule GJ.
    Urology; 1997 May 01; 49(5):795-801. PubMed ID: 9145995
    [Abstract] [Full Text] [Related]

  • 18. Rhenium-188-HEDP in the palliative treatment of bone metastases.
    Liepe K, Hliscs R, Kropp J, Grüning T, Runge R, Koch R, Knapp FF, Franke WG.
    Cancer Biother Radiopharm; 2000 Jun 01; 15(3):261-5. PubMed ID: 10941533
    [Abstract] [Full Text] [Related]

  • 19. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
    Zafeirakis A, Zissimopoulos A, Baziotis N, Limouris GS.
    Q J Nucl Med Mol Imaging; 2011 Feb 01; 55(1):91-102. PubMed ID: 21068716
    [Abstract] [Full Text] [Related]

  • 20. Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones.
    Uehara T, Jin ZL, Ogawa K, Akizawa H, Hashimoto K, Nakayama M, Arano Y.
    Nucl Med Biol; 2007 Jan 01; 34(1):79-87. PubMed ID: 17210464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.